CN112924672A - Biomarker for diagnosing rheumatoid arthritis combined with pulmonary interstitial fibrosis and application thereof - Google Patents
Biomarker for diagnosing rheumatoid arthritis combined with pulmonary interstitial fibrosis and application thereof Download PDFInfo
- Publication number
- CN112924672A CN112924672A CN202110120980.9A CN202110120980A CN112924672A CN 112924672 A CN112924672 A CN 112924672A CN 202110120980 A CN202110120980 A CN 202110120980A CN 112924672 A CN112924672 A CN 112924672A
- Authority
- CN
- China
- Prior art keywords
- lectin
- binding
- igg
- rheumatoid arthritis
- lca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 42
- 208000005069 pulmonary fibrosis Diseases 0.000 title claims abstract description 15
- 239000000090 biomarker Substances 0.000 title claims abstract description 14
- 108090001090 Lectins Proteins 0.000 claims abstract description 87
- 102000004856 Lectins Human genes 0.000 claims abstract description 87
- 239000002523 lectin Substances 0.000 claims abstract description 87
- 230000027455 binding Effects 0.000 claims abstract description 42
- 210000002966 serum Anatomy 0.000 claims abstract description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 239000012472 biological sample Substances 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 3
- 239000004816 latex Substances 0.000 claims description 3
- 229920000126 latex Polymers 0.000 claims description 3
- 239000002071 nanotube Substances 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 238000002493 microarray Methods 0.000 abstract description 17
- 208000029523 Interstitial Lung disease Diseases 0.000 abstract description 16
- 150000004676 glycans Chemical class 0.000 abstract description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 10
- 239000008103 glucose Substances 0.000 abstract description 9
- 101710186708 Agglutinin Proteins 0.000 abstract description 8
- 101710146024 Horcolin Proteins 0.000 abstract description 8
- 101710189395 Lectin Proteins 0.000 abstract description 8
- 101710179758 Mannose-specific lectin Proteins 0.000 abstract description 8
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 abstract description 8
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 abstract description 8
- 239000000910 agglutinin Substances 0.000 abstract description 8
- 230000013595 glycosylation Effects 0.000 description 13
- 238000006206 glycosylation reaction Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 108010048090 soybean lectin Proteins 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- 241000208296 Datura Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 244000179886 Moringa oleifera Species 0.000 description 1
- 235000011347 Moringa oleifera Nutrition 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 244000058477 Sambucus melanocarpa Species 0.000 description 1
- 235000007052 Sambucus melanocarpa Nutrition 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 235000011022 black elderberry Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 108010034897 lentil lectin Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108091000699 pea lectin Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000008163 sugars Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
- G01N2333/42—Lectins, e.g. concanavalin, phytohaemagglutinin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Rehabilitation Therapy (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses an application of LCA agglutinin in preparing a reagent for diagnosing rheumatoid arthritis and pulmonary interstitial fibrosis. The invention detects the glycan profile of the serum IgG molecule of a Rheumatoid Arthritis (RA) patient specifically combined with the agglutinin by adopting an agglutinin microarray, and the result shows that the content of LCA agglutinin combined glycan is increased in the RA patient. Since LCA lectin is specifically binding to glucose, this indicates that the expression of glucose levels is elevated in RA patients. Further studies found that LCA lectin-binding glycan levels were expressed higher in patients with RA-associated interstitial lung disease (RA-ILD) than in patients with non-ILD, and LCA lectin-binding glycan levels could serve as a biomarker for RA-ILD.
Description
Technical Field
The invention belongs to the field of biological detection, and particularly relates to a biomarker for diagnosing rheumatoid arthritis combined with pulmonary interstitial fibrosis and application thereof.
Background
Rheumatoid Arthritis (RA) is a common rheumatic immune disease, a chronic systemic immune disease with joint synovial lesions as the main characteristic, and the main clinical characteristics are chronic symmetrical joint swelling and pain, synovitis, joint tenderness with morning stiffness, joint function loss and extraarticular organ involvement. Research shows that about 500 million RA patients exist at present in China, and more than 80 percent of the patients who do not reach clinical remission bring heavy burden to patients, families and society. The disease is a typical '5D' disease which causes disability, death and pain, has great side effects on treatment medicines and causes huge economic loss, and has attracted high attention of clinical workers. Currently, clinical biomarkers for diagnosing RA and even RA-related pulmonary interstitial disease (RA-ILD) have certain limitations, and sensitivity and specificity caused by different methodologies are different, so that new biomarkers are urgently needed for early diagnosis and early treatment of RA-ILD.
Immunoglobulin-linked glycans affect the effector functions of antibodies, depending on the branching structure of the N-glycans and/or terminal sugars of the N-glycans or O-glycans, including galactose and sialic acid. IgG is the highest serum content of Ig and is structurally classified into a receptor-binding Fc fragment and a Fab arm that binds to an antigen. Research shows that autoimmune diseases have unique glycosylation expression profiles and play an important role in the occurrence and development of the autoimmune diseases. For example, abnormal levels of glycosylation of the Fc portion of serum IgG can result in changes in immune effector functions such as antibody-dependent cell-mediated cytotoxicity, antibody-dependent cell-mediated phagocytosis, or complement-dependent cytotoxicity of the body. In addition, the abnormal level of glycosylation of the Fab fragment of IgG affects antibody half-life in vivo, alters antibody stability and aggregation, leads to survival of malignant B cells through glycan signaling pathways, and is associated with intravenous immunoglobulin anti-inflammatory activity. Therefore, the research of glycosylation becomes a potential tool for deeply understanding the pathogenesis, disease classification, disease evaluation, treatment effect, prognosis judgment and disease outcome of autoimmune diseases.
In view of the important role of glycosylation in diseases, we intend to screen the expression of serum IgG glycosylation of RA-ILD patients by a high-throughput glycosylation analysis technology, namely a lectin microarray technology, so as to investigate the clinical application value of glycosylation in RA-ILD.
Disclosure of Invention
In order to solve the problems, the invention provides a biomarker for diagnosing rheumatoid arthritis and pulmonary interstitial fibrosis and application thereof.
First, the present invention provides a biomarker for diagnosing rheumatoid arthritis with pulmonary interstitial fibrosis, which is a complex formed by binding LCA lectin to IgG.
Wherein said IgG comprises glucose.
Secondly, the invention also provides the application of the biomarker in preparing a reagent for diagnosing rheumatoid arthritis.
Specifically, the diagnosis includes: determining the level of a complex formed by binding of LCA lectin to IgG in a biological sample obtained from a patient exhibiting rheumatoid arthritis; optionally, the step of (a) is carried out,
comparing the level of the complex formed by binding of LCA lectin to IgG in the biological sample to control data, wherein a detectably increased level of the complex formed by binding of LCA lectin to IgG in the sample relative to the control data is indicative of a likelihood of rheumatoid arthritis.
Further, detectably elevated levels of complexes formed by binding of LCA lectin to IgG are indicative of a likelihood of rheumatoid joint-associated pulmonary interstitial fibrosis relative to data from rheumatoid arthritis patients without associated pulmonary interstitial fibrosis.
Wherein the biological sample is a serum sample.
The invention also provides the use of LCA lectin in the manufacture of a reagent for the diagnosis of rheumatoid arthritis.
Wherein the diagnosing comprises: contacting LCA lectin with a biological sample obtained from a patient exhibiting rheumatoid arthritis and determining the level of complexes formed by binding of LCA lectin to IgG; optionally, the step of (a) is carried out,
comparing the level of the complex formed by binding of LCA lectin to IgG in the biological sample to control data, wherein a detectably increased level of the complex formed by binding of LCA lectin to IgG in the sample relative to the control data is indicative of a likelihood of rheumatoid arthritis.
Further, detectably elevated levels of complexes formed by binding of LCA lectin to IgG are indicative of a likelihood of rheumatoid joint-associated pulmonary interstitial fibrosis relative to data from rheumatoid arthritis patients without associated pulmonary interstitial fibrosis.
Wherein the biological sample is a serum sample.
In a particular embodiment of the invention, the level of the complex formed by the binding of LCA lectin to IgG is measured by the steps comprising:
a. contacting a biological sample from a patient with LCA lectin;
b. forming a lectin-glycan complex between IgG and LCA lectin present in the biological sample;
c. washing to remove any unbound IgG;
d. adding a detection antibody that is labeled and reactive with an antibody from the biological sample;
e. washing to remove any unbound labeled detection antibody; and
f. converting the label of the detection antibody to a detectable signal.
Wherein said LCA lectin is deposited or immobilized on a solid surface support.
The solid phase surface carrier is preferably in the form of latex beads, porous plates or membrane strips, nano-tubes, flakes with two-dimensional codes and the like.
Wherein the detection antibody is labeled by covalent attachment to an enzyme, a label with a fluorescent compound or metal, or a label with a chemiluminescent compound.
In another aspect, the present invention also provides a diagnostic kit for detecting and/or quantifying IgG capable of binding to LCA lectin in a biological sample, comprising: a solid surface support, wherein said LCA lectin is deposited on or immobilized on the solid surface support, wherein a complex formed by the binding of the LCA lectin to IgG serves as a biomarker for rheumatoid arthritis and interstitial pulmonary fibrosis.
In a preferred embodiment of the invention, the kit further comprises a detection antibody which is labeled and reactive with an antibody from the biological sample.
Preferably, the solid surface support is in the form of latex beads, porous plates or membrane strips, nanotubes, flakes with two-dimensional codes, or the like.
The invention detects the glycan profile of the serum IgG molecule of a Rheumatoid Arthritis (RA) patient specifically combined with the agglutinin by adopting an agglutinin microarray, and the result shows that the content of LCA agglutinin combined glycan is increased in the RA patient. Since LCA lectin is specifically binding to glucose, this indicates that the expression of glucose levels is elevated in RA patients. Further studies found that LCA lectin-binding glycan levels were expressed higher in patients with RA-associated interstitial lung disease (RA-ILD) than in patients with non-ILD, and LCA lectin-binding glycan levels could serve as a biomarker for RA-ILD.
Drawings
FIG. 1 shows the layout of a lectin microarray of 56 lectins (three wells) on an array slide.
FIG. 2 shows comparison of LCA lectin signal values for the RA-ILD group, RA-non ILD group, DC group and HC group.
FIG. 3 shows the ConA lectin stamp verification chart of the same lot of the lectin microarray.
FIG. 4 shows comparison of LCA lectin blot results of the same lot of the lectin microarray.
Fig. 5 shows the validation of LCA lectin stamp for the new batch of specimens.
Fig. 6 comparison of LCA lectin blot results grey scale values for new batch samples.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
Experimental specimen: subjects included in this study were divided into three groups: RA group (35, of which 15 RA-ILDs), disease control group (DC, including 40 autoimmune diseases, of which 20 systemic lupus erythematosus, 20 idiopathic inflammatory myopathy), healthy control group (HC, including 43 healthy examiners). The subject data are shown in Table 1. Wherein the diagnosis of both the RA group and the DC group meets the diagnosis criteria of the corresponding disease. All the people who entered the group collected fresh blood, and immediately separated serum, and frozen at-80 ℃ for later use.
TABLE 1 lectin microarray assay basic data for 118 subjects
Example 1 lectin microarray analysis of serum IgG glycosylation
A lectin microarray consisting of 56 kinds of lectin microparticles. 56 lectins were fixed in triplicate on a chip, and serum from each patient was diluted 1:200, added to the microarray and incubated overnight at 4 ℃. Then, the anti-IgG-Cy 5 conjugate was hybridized to the microarray chip for 1 hour in a dark environment. The fluorescence intensity of all proteins was analyzed independently. And converts the chip image to a digital format for analysis.
The signal-to-noise ratio (S/N) for each lectin spot was calculated using the signal-to-noise ratio (difference between foreground and background values for the spot) for each lectin spot. To prevent bias of lectin microarrays between arrays, we normalized the S/N data using normalization between arrays. Significant differences in lectin binding were determined by data distribution among groups according to the following rules (1) comparison between groups >1.7 or < 0.588; (2) the test types are compared between groups, if normality is met, T test is selected, otherwise non-parametric test is selected, if P value <0.05 or fisher test P value <0.05 or [ ROC _ AUC > -0.6 and ROC _ P value <0.05) ].
A lectin microarray containing 56 lectins was used to detect the glycosylation state in the experimental samples (FIG. 1). The lectin can be specifically combined with glycan molecules at the tail end of the glycoprotein to form a complex, and the type and content of the glycan on the surface of the target protein can be researched through the specific combination of different lectins and the glycan. Lectin microarrays are now being widely used in glycosylation research due to their high efficiency. After the frozen samples are balanced at room temperature, the samples are added into a lectin microarray to react with the lectin microarray, and then the signal value of each lectin and the specific binding glycan of each lectin can be obtained through the steps of washing, sealing, fluorescent secondary antibody reaction, fluorescence detection and the like, wherein the signal value is related to binding affinity and binding strength.
To ensure that the collected fluorescent signal is derived from a specific binding of IgG, we labeled IgG antibodies with Cy 5. The S/N data for the two lectins satisfying the above two conditions were considered to have significant differences, and 7 lectins were selected in total (Table 2).
Table 2 lectins with significant differences in lectin microarrays
Man: mannose; GlcNAc: n-acetylglucosamine; glc: glucose; GalNAc: n-acetylgalactosamine; gal: galactose; DC: a disease control group; HC: healthy control group. *: p < 0.05; **: p < 0.01.
The affinity signal values for the 6 lectins showed significant differences between the four groups of samples. S/N data show IgG glycosylation changes in the RA-ILD patient group relative to the RA-non ILD, DC and HC groups: (1) increased mannose sugar chains of RA-ILD patients were shown by detecting increased binding to concanavalin A (ConA) (P < 0.05); (2) an increase in N-acetylglucosamine (GlcNAc) in RA-ILD patients was indicated by detecting an increase in binding to Datura agglutinin (DSL) (< 0.05 for all P); (3) an increase in glucose (Glc) in RA-ILD patients was indicated by detecting increased binding to lentil Lectin (LCA) and pea lectin (PSA) (both P < 0.05); (4) an increase in galactose (Gal) in RA-ILD patients (both P <0.05) was indicated by detecting an increase in binding to Moringa oleifera lectin (black elderberry) (MNA-M); (5) by detecting a decrease in binding to soybean lectin (SBA), a decrease in N-acetylgalactosamine (GalNAc) in RA-ILD patients was indicated (P both < 0.05). FIG. 2 shows LCA lectin signal comparison for the RA-ILD, RA-non ILD, DC and HC groups.
Example 2 serolectin imprinting validation experiment
To further clarify the differential expression glycosylation detected by the lectin microarray, lectin imprinting was performed using 12 samples of the same lot (6 RA-ILD and 6 RA-non ILD) and a new lot (12 samples of the same lot (5 RA-ILD and 7 RA-non ILD, for the basic data shown in Table 3) of the lectin microarray. Serum specimen 1: 100, mixing with a loading buffer solution, boiling for 5 minutes at 100 ℃, performing SDS-PAGE electrophoresis in 10% preformed gel, and electrically transferring proteins in the preformed gel to a PVDF membrane. And (3) sealing the PVDF film which is successfully transferred, hybridizing the PVDF film with Cy 3-labeled lectin, and finally detecting a fluorescence signal by a fluorescence imager. The intensity of the fluorescence signal is proportional to the binding force of the lectin-bound glycoprotein glycosyl groups.
By comparing the results of lectin blotting on 12 micro-aligned batches of patient specimens (fig. 3), the binding strength of serum IgG to LCA lectin was increased in RA-non ILD patients compared to RA-non ILD patients (fig. 4). Furthermore, comparison of the results of lectin blotting on 12 new batches of patient specimens (fig. 5) revealed that the binding strength of serum IgG to LCA lectin was also significantly increased in RA-ILD patients (P <0.05 for all) compared to RA-non ILD patients (fig. 6).
The above results indicate that LCA lectin-bound glycan-glucose levels are abnormal in the serum of RA-ILD patients, and RA-ILD patients have higher LCA lectin-bound glycan levels than RA-non ILD patients.
TABLE 3 lectin blot validation of disease data for New batch RA patients
The results indicate that LCA lectin-binding glycan levels are expressed higher in RA-ILD patients than in RA-non ILD patients, indicating that LCA lectin-binding glycan levels can serve as a biological marker for RA-ILD.
Claims (10)
1. A biomarker for diagnosing rheumatoid arthritis with pulmonary interstitial fibrosis, which is a complex formed by binding of LCA lectin and IgG.
2. Use of the biomarker of claim 1 for the preparation of a reagent for the diagnosis of rheumatoid arthritis.
3. The use of claim 2, wherein said diagnosing comprises: determining the level of a complex formed by binding of LCA lectin to IgG in a biological sample obtained from a patient exhibiting rheumatoid arthritis; optionally, the step of (a) is carried out,
comparing the level of the complex formed by binding of LCA lectin to IgG in the biological sample to control data, wherein a detectably increased level of the complex formed by binding of LCA lectin to IgG in the sample relative to the control data is indicative of a likelihood of rheumatoid arthritis.
4. The use of claim 3, wherein a detectably increased level of a complex formed by binding of LCA lectin to IgG is indicative of a likelihood of rheumatoid joint-associated pulmonary interstitial fibrosis, relative to data from a patient with rheumatoid arthritis not associated with pulmonary interstitial fibrosis.
Use of LCA lectin in the manufacture of a reagent for the diagnosis of rheumatoid arthritis.
6. The use of claim 5, wherein said diagnosing comprises: contacting LCA lectin with a biological sample obtained from a patient exhibiting rheumatoid arthritis and determining the level of complexes formed by binding of LCA lectin to IgG; optionally, the step of (a) is carried out,
comparing the level of the complex formed by binding of LCA lectin to IgG in the biological sample to control data, wherein a detectably increased level of the complex formed by binding of LCA lectin to IgG in the sample relative to the control data is indicative of a likelihood of rheumatoid arthritis.
7. The use of claim 6, wherein a detectably increased level of a complex formed by binding of LCA lectin to IgG is indicative of a likelihood of rheumatoid joint-associated pulmonary interstitial fibrosis relative to data from a rheumatoid arthritis patient not associated with pulmonary interstitial fibrosis.
8. The use according to claim 3 or 6, wherein the biological sample is a serum sample.
9. The use of claim 3 or 6, wherein the level of a complex formed by binding of LCA lectin to IgG is measured by the steps comprising:
a. contacting a biological sample from a patient with LCA lectin;
b. forming a lectin-glycan complex between IgG and LCA lectin present in the biological sample;
c. washing to remove any unbound IgG;
d. adding a detection antibody that is labeled and reactive with an antibody from the biological sample;
e. washing to remove any unbound labeled detection antibody; and
f. converting the label of the detection antibody to a detectable signal.
10. Use according to claim 9, wherein the LCA lectin is deposited or immobilized on a solid surface support, preferably in the form of a latex bead, a multi-well plate or membrane strip, a nanotube, a two-dimensional coded sheet or the like, preferably the detection antibody is labeled by covalent attachment to an enzyme, a label with a fluorescent compound or metal, or a label with a chemiluminescent compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110120980.9A CN112924672A (en) | 2021-01-28 | 2021-01-28 | Biomarker for diagnosing rheumatoid arthritis combined with pulmonary interstitial fibrosis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110120980.9A CN112924672A (en) | 2021-01-28 | 2021-01-28 | Biomarker for diagnosing rheumatoid arthritis combined with pulmonary interstitial fibrosis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112924672A true CN112924672A (en) | 2021-06-08 |
Family
ID=76168181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110120980.9A Pending CN112924672A (en) | 2021-01-28 | 2021-01-28 | Biomarker for diagnosing rheumatoid arthritis combined with pulmonary interstitial fibrosis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112924672A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060141547A1 (en) * | 2004-11-16 | 2006-06-29 | Das Hasi R | Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis |
| WO2006114661A1 (en) * | 2005-04-26 | 2006-11-02 | Dwek Raymond A | High throughput glycan analysis for diagnosing and monitoring rheumatoid arthritis and other autoimmune diseases |
| CN101074951A (en) * | 2007-06-26 | 2007-11-21 | 大连医科大学 | Immune globulin G-glycosylation inspecting reagent for rheumatic arthritis in early-stage diagnosis and its production |
| US20130212720A1 (en) * | 2010-06-11 | 2013-08-15 | The Regents Of The University Of California | Biomarkers associated with autoimmune diseases of the lung |
| CN107076742A (en) * | 2014-10-30 | 2017-08-18 | 国立研究开发法人产业技术综合研究所 | Rheumatoid arthritis mark |
| CN108700585A (en) * | 2015-12-23 | 2018-10-23 | 兰多克斯实验室有限公司 | Glycosylate the determination of feature |
-
2021
- 2021-01-28 CN CN202110120980.9A patent/CN112924672A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060141547A1 (en) * | 2004-11-16 | 2006-06-29 | Das Hasi R | Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis |
| WO2006114661A1 (en) * | 2005-04-26 | 2006-11-02 | Dwek Raymond A | High throughput glycan analysis for diagnosing and monitoring rheumatoid arthritis and other autoimmune diseases |
| CN101074951A (en) * | 2007-06-26 | 2007-11-21 | 大连医科大学 | Immune globulin G-glycosylation inspecting reagent for rheumatic arthritis in early-stage diagnosis and its production |
| US20130212720A1 (en) * | 2010-06-11 | 2013-08-15 | The Regents Of The University Of California | Biomarkers associated with autoimmune diseases of the lung |
| CN107076742A (en) * | 2014-10-30 | 2017-08-18 | 国立研究开发法人产业技术综合研究所 | Rheumatoid arthritis mark |
| CN108700585A (en) * | 2015-12-23 | 2018-10-23 | 兰多克斯实验室有限公司 | Glycosylate the determination of feature |
Non-Patent Citations (1)
| Title |
|---|
| J. STÜMER等: "Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy", 《CLINICAL AND EXPERIMENTAL IMMUNOLOGY》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patwa et al. | Glycoprotein analysis using protein microarrays and mass spectrometry | |
| AU2018202110B2 (en) | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender- based disease identification, assessment, prevention and therapy | |
| CN109342727B (en) | Esophageal squamous cell carcinoma autoantibody molecular marker model and application thereof | |
| AU2016378909B2 (en) | Determination of glycosylation signature | |
| CN112924671A (en) | Biomarker for diagnosing rheumatoid arthritis combined with pulmonary interstitial fibrosis and application thereof | |
| CN113009130B (en) | Biomarker for diagnosing primary sicca syndrome and application thereof | |
| CN112924672A (en) | Biomarker for diagnosing rheumatoid arthritis combined with pulmonary interstitial fibrosis and application thereof | |
| CN110865191A (en) | Biomarker for diagnosing anti-MDA 5 antibody positive idiopathic inflammatory myositis and application thereof | |
| CN112924673A (en) | Biomarker for diagnosing rheumatoid arthritis combined with pulmonary interstitial fibrosis and application thereof | |
| CN115418403A (en) | Method and reagent for diagnosing pancreatic cystic tumor | |
| CN115372616A (en) | Gastric cancer related biomarker and application thereof | |
| CN112630433B (en) | Biomarker combination for detecting gastric cancer autoantibody and application thereof | |
| CN110865190A (en) | Biomarker for diagnosing anti-Jo 1 antibody negative idiopathic inflammatory myositis and application thereof | |
| CN110865189A (en) | Biomarker for diagnosing anti-TIF 1 gamma antibody positive idiopathic inflammatory myositis and application thereof | |
| US8741288B2 (en) | Protein markers for detecting liver cancer and method for identifying the markers thereof | |
| CN110031632A (en) | A kind of biomarker of Disease Activity and application thereof that reflection IgG4 is diseases related | |
| CN113009131A (en) | Biomarker for diagnosing primary sicca syndrome and application thereof | |
| CN113009149A (en) | Sugar chain marker for diagnosing PBC patients positive and negative to AMA-M2 antibody and application thereof | |
| CN110045125B (en) | Biomarker for diagnosing retroperitoneal fibrosis and application thereof | |
| CN113009148A (en) | Sugar chain marker for diagnosing PBC patients positive and negative to SP100 antibody and application thereof | |
| CN113281519A (en) | Sugar chain marker for diagnosing PBC patients positive and negative to ACA antibody and use thereof | |
| CN110045126B (en) | Biomarker for diagnosing autoimmune pancreatitis and application thereof | |
| CN113009147A (en) | Sugar chain marker for diagnosing anti-gp 210 antibody positive and negative PBC patients and application thereof | |
| CN115327131A (en) | Biomarker for identifying Takayasu arteritis and application thereof | |
| CN115308420A (en) | Biomarker for reflecting disease activity of Takayasu arteritis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210608 |